Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec 8;13(12):3001.
doi: 10.3390/biomedicines13123001.

Comparable Immune Alterations and Inflammatory Signatures in ME/CFS and Long COVID

Affiliations

Comparable Immune Alterations and Inflammatory Signatures in ME/CFS and Long COVID

Steliyan Petrov et al. Biomedicines. .

Abstract

Background: Chronic Fatigue Syndrome (CFS), also known as Myalgic Encephalomyelitis (ME), is a debilitating condition characterized by persistent fatigue and multisystemic symptoms, such as cognitive impairment, musculoskeletal pain, and post-exertional malaise. Recently, parallels have been drawn between ME/CFS and Long COVID, a post-viral syndrome following infection with SARS-CoV-2, which shares many clinical features with CFS. Both conditions involve chronic immune activation, raising questions about their immunopathological overlap. Objectives: This study aimed to compare immune biomarkers between patients with ME/CFS or Long COVID and healthy controls to explore shared immune dysfunction. Methods: We analyzed lymphocyte subsets, cytokine profiles, psychological status and their correlations in 190 participants, 65 with CFS, 54 with Long COVID, and 70 healthy controls. Results: When compared to healthy subjects, results in both conditions were marked by lower levels of lymphocytes (CFS-2.472 × 109/L, p = 0.006, LC-2.051 × 109/L, p = 0.009), CD8+ T cells (CFS-0.394 × 109/L, p = 0.001, LC-0.404 × 109/L, p = 0.001), and NK cells (CFS-0.205 × 109/L, p = 0.001, LC-0.180 × 109/L, p = 0.001), and higher levels of proinflammatory cytokines such as IL-6 (CFS-3.35 pg/mL, p = 0.050 LC-4.04 pg/mL, p = 0.001), TNF (CFS-2.64 pg/mL, p = 0.023, LC-2.50 pg/mL, p = 0.025), IL-4 (CFS-3.72 pg/mL, p = 0.041, LC-3.45 pg/mL, p = 0.048), and IL-10 (CFS-2.29 pg/mL, p = 0.039, LC-2.25 pg/mL, p = 0.018). Conclusions: Notably, there were no significant differences between CFS and Long COVID patients in the tested biomarkers. These results demonstrate that ME/CFS and Long COVID display comparable immune and inflammatory profiles, with no significant biomarker differences observed between the two groups.

Keywords: COVID-19; chronic fatigue; chronic fatigue syndrome; long COVID.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Results from age-adjusted ANCOVA test, showing distribution of lymphocytes, NK and CD8+ T cells in the three studied groups as individual points (circles). Exact p values are provided. Results are presented as median values and interquartile ranges (coloured lines).
Figure 2
Figure 2
Results from age-adjusted ANCOVA test, showing serum levels of IFN-γ, TNF, IL-4, IL-2, IL-10, and IL-6 in the three studied groups as individual points (circles). Exact p values are provided where statistical significance was established. Results are presented as median values and interquartile ranges (coloured lines).
Figure 3
Figure 3
Results from age-adjusted ANCOVA test, showing z-score ratios of Th1 ctokine profile, Th1/Th2 + Treg ratio, proinflamatory/antiinflammatory profile, and IRC/CIRS ratio in the three studied groups as individual points (circles). Exact p values are provided where statistical significance was established. Results are presented as median values and interquartile ranges (coloured lines).

References

    1. Pollard C.A., Morran M.P., Nestor-Kalinoski A.L. The COVID-19 pandemic: A global health crisis. Physiol. Genom. 2020;52:549–557. doi: 10.1152/physiolgenomics.00089.2020. - DOI - PMC - PubMed
    1. Li J., Huang D.Q., Zou B., Yang H., Hui W.Z., Rui F., Yee N.T.S., Liu C., Nerurkar S.N., Kai J.C.Y., et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J. Med. Virol. 2021;93:1449–1458. doi: 10.1002/jmv.26424. - DOI - PMC - PubMed
    1. Di Gennaro F., Pizzol D., Marotta C., Antunes M., Racalbuto V., Veronese N., Smith L. Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. Int. J. Environ. Res. Public Health. 2020;17:2690. doi: 10.3390/ijerph17082690. - DOI - PMC - PubMed
    1. Somani S., Agnihotri S.P. Emerging Neurology of COVID-19. Neurohospitalist. 2020;10:281–286. doi: 10.1177/1941874420936096. - DOI - PMC - PubMed
    1. Mao R., Qiu Y., He J.S., Tan J.Y., Li X.H., Liang J., Shen J., Zhu L.R., Chen Y., Iacucci M., et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: A systematic review and meta-analysis. The Lancet Gastroenterol. Hepatol. 2020;5:667–678. doi: 10.1016/S2468-1253(20)30126-6. Erratum in The Lancet Gastroenterol. Hepatol. 2025, 5, e6. https://doi.org/10.1016/S2468-1253(20)30160-6 . - DOI - PMC - PubMed

LinkOut - more resources